Company Profile
Tango Therapeutics Stock Price, News & Catalysts
- Ticker:
- TNGX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
22.71 USD (+3.75%)
Close
Last updated: November 19, 2026
3.11B USD
Market cap
Why the stock is moving
As of Nov 19, 2026, TNGX closed up 3.75% at $22.71. No new same-company headline was identified in the current news window.
Company overview
Synthetic Lethality Oncology Company
Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss.
Vopimetostat
Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in RAS-mutant tumors.
RAS(ON) Combination Strategy
The company is combining vopimetostat with RAS(ON) inhibitors in pancreatic and lung cancers carrying both MTAP deletion and RAS mutations.
TNG456
TNG456 is a next-generation PRMT5 inhibitor being evaluated in glioblastoma and other MTAP-deleted cancers, extending Tango's synthetic-lethality strategy into tumors where brain penetration is important.
Future catalysts
- Vopimetostat monotherapy data in lung cancer and TNG456 data in lung cancer, glioblastoma, and other cancers in January 2027.
- Initiation of a Phase 3 study of vopimetostat plus daraxonrasib in frontline MTAP-deleted pancreatic cancer in the first half of 2027.
- Initiation of a Phase 1/2 vopimetostat-plus-pan-RAS-inhibitor study in MTAP-wild-type pancreatic cancer in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tango Therapeutics (TNGX)?
Tango Therapeutics (TNGX) most recently closed at 22.71 USD, a +3.75% move versus the previous session.
What is the market cap of Tango Therapeutics (TNGX)?
Tango Therapeutics currently has a market capitalization of 3.11B USD on BioPharmSignal.
What does Tango Therapeutics do?
Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen responses in...
On which exchange is TNGX stock listed?
Tango Therapeutics (TNGX) is associated with NASDAQ, United States, Biopharma.
What is vopimetostat?
Vopimetostat monotherapy data in lung cancer and TNG456 data in lung cancer, glioblastoma, and other cancers in January 2027.
Which conditions is Tango Therapeutics targeting with vopimetostat?
Tango Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Tango Therapeutics describe recent progress with vopimetostat?
Vopimetostat monotherapy data in lung cancer and TNG456 data in lung cancer, glioblastoma, and other cancers in January 2027.
What is Synthetic?
Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss.
